B · Normal
[AbbVie: Icritumumab Injection Launched in China] On October 26, AbbVie announced on the 26th that its CD3×CD20 bispecific antibody Ikorel® (icorelatumumab injection) was officially launched in China as a bispecific antibody for the treatment of relapsed or refractory (R/R) follicular lymphoma (FL). The launch of Acela® marks the beginning of a new stage of dual-antibody therapy for the treatment of relapsed and refractory follicular lymphoma in China.
monoclonal antibody 🕐 2026-10-26 10:23
#monoclonal antibody
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

[Eli Lilly: The targeted anti-cancer drug Olomorasib shows durable activity in f 10-25 15:48 On October 24th, Eli Lilly announced data stating that the confirmed objective r 10-24 14:38 [Eli Lilly announced the latest data from the clinical study of the combination 10-11 09:37 [Merck’s PD-1 inhibitor pembrolizumab injection (subcutaneous injection) approve 09-29 16:32 [Junshi Biology: New drugs JS203 and JS207 are expected to start Phase III clini 09-14 13:17 [Hengrui Medicine: Many of its main products will have expanded indications this 09-10 14:42

Comments

0/500
Captcha (click to refresh)
No comments yet